Aspira Women's Health AWHL
OTC AWHL
$0.22 +0.00 (+0.00%)
As of: Oct 23, 2026 · 10:21 AM EDT

Aspira Women's Health (AWHL) Exchange Rate Effect (2010 - 2012)

Updated

Aspira Women's Health (AWHL) recorded Exchange Rate Effect of $2,000 in Q2 2012, unchanged from $2,000 a year earlier.

Analysis

Aspira Women's Health (AWHL) Exchange Rate Effect (2010 - 2012) Analysis & Trends

For FY2011, Aspira Women's Health reported Exchange Rate Effect of $3,000, down 66.7% from FY2010.

  • Across earlier years, Exchange Rate Effect came in at $9,000 in FY2010.
  • Quarterly Exchange Rate Effect has ranged from -$3,000 in Q1 2012 to $3,000 in Q3 2011 over the past five years.
  • Per Business Quant, the preceding three quarters came in at -$3,000 (Q1 2012), -$1,000 (Q4 2011) and $3,000 (Q3 2011).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) FX Effect (Qtr)
1 HCA Healthcare 103.18 Bn 99.19 Bn - -1.00 Mn
2 Natera 57.81 Bn 53.49 Bn 485.19 Mn -
3 Labcorp Holdings 26.94 Bn 24.69 Bn 1.11 Bn 1.30 Mn
4 Quest Diagnostics 26.85 Bn 24.98 Bn 1.03 Bn -1.00 Mn
5 Guardant Health 22.51 Bn 18.57 Bn 219.03 Mn -411,000.00
6 Tenet Healthcare 22.37 Bn 11.37 Bn - -
7 Fresenius Medical Care AG 13.20 Bn 5.15 Bn 1.52 Bn 2.45 Mn
8 BrightSpring Health Services 12.39 Bn 10.72 Bn 492.75 Mn -
9 Encompass Health 12.26 Bn 11.92 Bn - -
10 Aspira Women's Health 9.51 Mn 2.13 Mn 1.13 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2012 2,000.00
Mar 31, 2012 -3,000.00
Dec 31, 2011 -1,000.00
Sep 30, 2011 3,000.00
Jun 30, 2011 2,000.00
Mar 31, 2011 -1,000.00
Dec 31, 2010 3,000.00
Sep 30, 2010 3,000.00
API Access

Aspira Women's Health Exchange Rate Effect API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=exchange-rate-effect&ticker=AWHL&period=max&api_key=YOUR_API_KEY